CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Boceprevir triple therapy of chronic HCV genotype 1 (G1) infection in previously untreated patients: Efficacy, predictability of virologic response and safety in German real-life
DOI 10.1055/s-0035-1567994
Bibliografische Angaben
Nachweis in CareLit
Autor:innenP Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, P Geyer, B Weber, T Witthöft, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe12/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Since 2011, triple therapy with the HCV protease inhibitor boceprevir (BOC) is widely used as standard of care for patients (pts) with chronic HCV G1 infection. Here we report the German experience obtained from the NOVUS observational study with respect to efficacy, safety and predictability of virologic outcome in previously untreated pts undergoing BOC triple therapy in real-life. Methods: From April…
Zitieren
Zitierempfehlung
P Buggisch, H Löhr, G Teuber, H Steffens, M Kraus, P Geyer, B Weber, T Witthöft, U Naumann, E Zehnter, D Hartmann, B Dreher, M Bilzer (2015) Boceprevir triple therapy of chronic HCV genotype 1 (G1) infection in previously untreated patients: Efficacy, predictability of virologic response and safety in German real-life. Zeitschrift für Gastroenterologie (12). https://doi.org/10.1055/s-0035-1567994
Mit CareLit weiterarbeiten